Clinical trial
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
NCT00394082 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00394082 |
|---|---|
| Title | ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer |
| Official title | A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | ABI-007, Bevacizumab |
| Enrollment | 50 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Feb 1, 2011 |
| First posted | Oct 31, 2006 |
| Last update posted | Nov 25, 2019 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: